The cannabis plant contains more than 560 chemical compounds, including over 100 cannabinoids, which interact with the human endocannabinoid system—a network involved in regulating sleep, pain, inflammation, immune responses, and appetite. Among these cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent and studied for their distinct effects on the body.

THC is the primary psychoactive component of cannabis responsible for the characteristic “high.” It activates CB1 receptors in the brain, which leads to intoxication. Beyond recreational effects, THC has documented therapeutic uses. Synthetic THC formulations are approved by the U.S. Food and Drug Administration (FDA) for treating chemotherapy-induced nausea and vomiting, as well as weight and appetite loss in patients with HIV/AIDS. Recent research in Germany found that THC-containing medications reduced nightmares in over a third of patients with post-traumatic stress disorder (PTSD) after 10 weeks of treatment.

However, frequent and high-dose THC use carries risks. It may contribute to cannabinoid hyperemesis syndrome, a condition marked by cyclic vomiting. Up to 30% of cannabis users may develop cannabis use disorder, which involves tolerance, compulsive consumption, and impaired control. THC exposure has also been linked to earlier onset and exacerbated symptoms of psychosis and schizophrenia, particularly in individuals genetically predisposed or who began using cannabis during adolescence.

Unlike THC, CBD does not produce intoxication or have the same potential for abuse. While its precise mechanisms remain under investigation, CBD influences various brain receptors, including the transient receptor potential vanilloid 1 (TRPV1) receptor involved in seizure activity. In 2020, the FDA approved an oral CBD formulation as a treatment for certain epileptic conditions, marking a significant milestone. CBD also appears to interact with serotonin receptors, which could explain its potential benefits for mood regulation.

Ongoing studies explore CBD’s use in managing chronic pain, anxiety, social interaction challenges in autism, and substance use disorders. Its appeal lies partly in providing symptom relief without impairment. Often, CBD products incorporate small amounts of THC to leverage synergistic effects, although research is still defining optimal cannabinoid ratios for therapeutic outcomes.

Despite these promising attributes, CBD is not without concerns. High, frequent doses may pose liver toxicity risks and can interfere with the metabolism of other medications, such as antidepressants, pain relievers, and blood thinners. Experts caution that many users are unaware of these interactions and might inadvertently experience adverse effects.

Legally, CBD derived from hemp—cannabis plants containing less than 0.3% THC—is federally permitted in the United States and widely available, including in convenience stores and smoke shops. This broad accessibility raises quality and safety issues, as unregulated products can be contaminated with toxins or may lack the advertised cannabinoid content.

Researchers emphasize the need for better regulation to ensure product consistency, proper dosing, and safety, making cannabis-based treatments more effective and reliable. Health professionals recommend consulting with a healthcare provider before starting any cannabis-derived therapies.

Experts remain optimistic about the future of cannabinoid medicines in addressing a range of health conditions. Cannabis is increasingly viewed not solely as a recreational drug but as a source of potentially transformative medical treatments.